[
  {
    "ts": null,
    "headline": "Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues",
    "summary": "RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.",
    "url": "https://finnhub.io/api/news?id=973675d14aa607dc38cf7951a6f8ea03116c8198333f0c3e780c5d23c7ea3652",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753370460,
      "headline": "Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues",
      "id": 136084963,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.",
      "url": "https://finnhub.io/api/news?id=973675d14aa607dc38cf7951a6f8ea03116c8198333f0c3e780c5d23c7ea3652"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?",
    "summary": "BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.",
    "url": "https://finnhub.io/api/news?id=501be251bd192d0235da68db1b3fa692c3a327e253e929f781afa5355f5a74f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753368540,
      "headline": "Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?",
      "id": 136084964,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.",
      "url": "https://finnhub.io/api/news?id=501be251bd192d0235da68db1b3fa692c3a327e253e929f781afa5355f5a74f0"
    }
  },
  {
    "ts": null,
    "headline": "Fibroblast Growth Factors (FGFs) Global Market Report 2025-2029 & 2034 | Regenerative Medicine Demand and Biotech Advancements Fueling Expansion",
    "summary": "The fibroblast growth factors (FGFs) market is projected to soar from $0.86 billion in 2024 to $1.34 billion by 2025, driven by advancements in regenerative medicine, wound healing, and cancer research. Key players like Merck & Co., Thermo Fisher, and Novartis are driving innovation. North America leads, with Asia-Pacific as a fast-growing contender.Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The \"Fibroblast Growth Factors (FGFs) Global Market Report 2025\" has been added to ResearchAndMarkets.com'",
    "url": "https://finnhub.io/api/news?id=b8cbdb94d8109d3bae5a1f6df6c92d5635fb1c26afbff6aef8a02d4759bea62f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753366440,
      "headline": "Fibroblast Growth Factors (FGFs) Global Market Report 2025-2029 & 2034 | Regenerative Medicine Demand and Biotech Advancements Fueling Expansion",
      "id": 136066358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The fibroblast growth factors (FGFs) market is projected to soar from $0.86 billion in 2024 to $1.34 billion by 2025, driven by advancements in regenerative medicine, wound healing, and cancer research. Key players like Merck & Co., Thermo Fisher, and Novartis are driving innovation. North America leads, with Asia-Pacific as a fast-growing contender.Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The \"Fibroblast Growth Factors (FGFs) Global Market Report 2025\" has been added to ResearchAndMarkets.com'",
      "url": "https://finnhub.io/api/news?id=b8cbdb94d8109d3bae5a1f6df6c92d5635fb1c26afbff6aef8a02d4759bea62f"
    }
  },
  {
    "ts": null,
    "headline": "How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?",
    "summary": "LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.",
    "url": "https://finnhub.io/api/news?id=3b7ca2d9b2013ad37d57522728e29525f5e55b17922fe474c9a6de14a9684973",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753365900,
      "headline": "How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?",
      "id": 136084782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.",
      "url": "https://finnhub.io/api/news?id=3b7ca2d9b2013ad37d57522728e29525f5e55b17922fe474c9a6de14a9684973"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=aa179e3192b2d4dd5fcf16e596654c71fa0f911160f0de02c25ed39c2f0187c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753365625,
      "headline": "AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
      "id": 136084836,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=aa179e3192b2d4dd5fcf16e596654c71fa0f911160f0de02c25ed39c2f0187c0"
    }
  },
  {
    "ts": null,
    "headline": "Exploring Analyst Estimates for Merck (MRK) Q2 Earnings, Beyond Revenue and EPS",
    "summary": "Beyond analysts' top-and-bottom-line estimates for Merck (MRK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.",
    "url": "https://finnhub.io/api/news?id=64d328a966c609a4ae6014601268c9823de0ccfd27376cccccad3eeffd900d8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753362903,
      "headline": "Exploring Analyst Estimates for Merck (MRK) Q2 Earnings, Beyond Revenue and EPS",
      "id": 136084967,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Beyond analysts' top-and-bottom-line estimates for Merck (MRK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.",
      "url": "https://finnhub.io/api/news?id=64d328a966c609a4ae6014601268c9823de0ccfd27376cccccad3eeffd900d8c"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=97d212179c615d0126066b8f5ac9580c51d8fafb63c3de237d8bb86e70eb8ce5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753362002,
      "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know",
      "id": 136066359,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=97d212179c615d0126066b8f5ac9580c51d8fafb63c3de237d8bb86e70eb8ce5"
    }
  },
  {
    "ts": null,
    "headline": "Diffuse Large B-cell Lymphoma Market Research Report 2025-2035 | Personalized Medicine and Precision Treatment Trends in DLBCL",
    "summary": "The Diffuse Large B-cell Lymphoma (DLBCL) market is witnessing significant growth, driven by advancements in targeted immunotherapies like CAR-T cell therapy and bispecific antibodies. These therapies are transforming the treatment landscape for relapsed or refractory cases, offering personalized, effective solutions. Despite exciting trends in precision medicine, the market faces challenges such as high treatment costs, resistance issues, and side effects associated with CAR-T therapy. However,",
    "url": "https://finnhub.io/api/news?id=acb747de31084bf7e4395f2a15d793cf18a3f91e9f2633ce65957db4eb27788c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753351140,
      "headline": "Diffuse Large B-cell Lymphoma Market Research Report 2025-2035 | Personalized Medicine and Precision Treatment Trends in DLBCL",
      "id": 136066252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Diffuse Large B-cell Lymphoma (DLBCL) market is witnessing significant growth, driven by advancements in targeted immunotherapies like CAR-T cell therapy and bispecific antibodies. These therapies are transforming the treatment landscape for relapsed or refractory cases, offering personalized, effective solutions. Despite exciting trends in precision medicine, the market faces challenges such as high treatment costs, resistance issues, and side effects associated with CAR-T therapy. However,",
      "url": "https://finnhub.io/api/news?id=acb747de31084bf7e4395f2a15d793cf18a3f91e9f2633ce65957db4eb27788c"
    }
  },
  {
    "ts": null,
    "headline": "Looking For Yields: Merck, Hormel Foods, And Spire Are Consistent Moneymakers",
    "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Merck, Hormel Foods, and Spire have rewarded shareholders for years and recently announced dividend increases. These companies ...",
    "url": "https://finnhub.io/api/news?id=2cdf40630b0b901ea41361f5ab0f180e3a924241c257045357d2087c144220fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753326620,
      "headline": "Looking For Yields: Merck, Hormel Foods, And Spire Are Consistent Moneymakers",
      "id": 136062250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Merck, Hormel Foods, and Spire have rewarded shareholders for years and recently announced dividend increases. These companies ...",
      "url": "https://finnhub.io/api/news?id=2cdf40630b0b901ea41361f5ab0f180e3a924241c257045357d2087c144220fe"
    }
  },
  {
    "ts": null,
    "headline": "Mountain Valley MD Holdings Announces Changes to Board of Directors",
    "summary": "TORONTO, July 24, 2025--Mountain Valley MD Holdings Inc. (the \"Company\" or \"MVMD\") (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce the appointment of David Batchelor to its board of directors.",
    "url": "https://finnhub.io/api/news?id=cfb25da818460eeeb06d794a1d0037c2c9d627621e03f3378cc9c135e1651755",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753321740,
      "headline": "Mountain Valley MD Holdings Announces Changes to Board of Directors",
      "id": 136062145,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "TORONTO, July 24, 2025--Mountain Valley MD Holdings Inc. (the \"Company\" or \"MVMD\") (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to announce the appointment of David Batchelor to its board of directors.",
      "url": "https://finnhub.io/api/news?id=cfb25da818460eeeb06d794a1d0037c2c9d627621e03f3378cc9c135e1651755"
    }
  }
]